

# Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Global Forecast to 2029

Market Report | 2025-01-22 | 407 pages | MarketsandMarkets

#### **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

#### **Report description:**

The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%." during the forecast period.

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

"The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period."

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and

growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.

"The intramuscular segment to capture the largest market share of veterinary vaccines market."

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.

"Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region."

The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
- By Designation: Directors-25%, Managers-50% and Others-25%
- By Region: North America-35%, Europe-30%, Asia Pacific-15% and RoW-20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogenesis Bago (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

### Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

### Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

-[]Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments), Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market

- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market

- Market Development: Comprehensive information on lucrative emerging regions

-[Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market

- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

## **Table of Contents:**

1 INTRODUCTION 33 1.1 STUDY OBJECTIVES 1.2 MARKET DEFINITION 33 1.3 STUDY SCOPE 34 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 34 1.3.2 INCLUSIONS & EXCLUSIONS 35 1.3.3 YEARS CONSIDERED 36 1.3.4 CURRENCY CONSIDERED 36 1.4 STAKEHOLDERS 36 1.5 SUMMARY OF CHANGES 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 39 2.1.1.1 Key secondary sources 39 2.1.1.2 Key data from secondary sources 40 2.1.2 PRIMARY DATA 40 2.1.2.1 Key primary sources 40 2.1.2.2 Objectives of primary research 41 2.1.2.3 Key data from primary sources 41 2.1.2.4 Key industry insights 42 2.1.2.5 Breakdown of primaries 42 2.2 MARKET SIZE ESTIMATION 44 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 44 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 46 2.2.3 TOP-DOWN APPROACH 48 2.3 DATA TRIANGULATION 49

2.4 MARKET SHARE ANALYSIS 50 2.5 STUDY ASSUMPTIONS 50 2.6 RISK ASSESSMENT 50 2.7 RESEARCH LIMITATIONS 51 2.7.1 METHODOLOGY-RELATED LIMITATIONS 51 2.7.2 SCOPE-RELATED LIMITATIONS 51 3 EXECUTIVE SUMMARY 52 ? 4 PREMIUM INSIGHTS 57 4.1 UETERINARY VACCINES MARKET OVERVIEW 57 4.2∏ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)∏58 4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 □ DRIVERS □ 61 5.2.1.1 Rise in companion animal population and pet ownership 61 5.2.1.2 Increasing incidence of infectious zoonotic diseases 62 5.2.1.3 Favorable initiatives by government agencies and animal associations∏62 5.2.1.4 Growing demand for animal-derived food products 63 5.2.1.5 Increased adoption of pet insurance and high animal health expenditure∏65 5.2.2 RESTRAINTS 66 5.2.2.1 High cost of vaccine development 66 5.2.3 OPPORTUNITIES 66 5.2.3.1 Technological advancements for veterinary vaccine development 66 5.2.3.2 Untapped growth potential in emerging economies 67 5.2.4 CHALLENGES 67 5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries 67 5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines 68 5.3 || INDUSTRY TRENDS || 68 5.4 TECHNOLOGY ANALYSIS 69 5.4.1 || KEY TECHNOLOGIES || 69 5.4.1.1 Recombinant DNA technology 69 5.4.1.2 mRNA-based vaccines 69 5.4.2 COMPLEMENTARY TECHNOLOGIES 70 5.4.2.1 Vaccine adjuvant technology 70 5.4.2.2 Needle-free and microneedle technology 70 5.4.3 ADJACENT TECHNOLOGIES 70 5.4.3.1 Genome editing technology 70 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS 71 5.6 SUPPLY CHAIN ANALYSIS 71 5.7 VALUE CHAIN ANALYSIS 73 5.8 TRADE ANALYSIS 74 5.8.1 IMPORT DATA FOR HS CODE 300242 74 5.8.2 EXPORT DATA FOR HS CODE 300230 75

?

5.9 PORTER'S FIVE FORCES ANALYSIS 75 5.9.1 THREAT OF NEW ENTRANTS 77 5.9.2 THREAT OF SUBSTITUTES 77 5.9.3 BARGAINING POWER OF SUPPLIERS 77 5.9.4 BARGAINING POWER OF BUYERS 77 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 78 5.10 KEY STAKEHOLDERS & BUYING CRITERIA 78 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 78 5.10.2 KEY BUYING CRITERIA 79 5.11 REGULATORY ANALYSIS 80 5.11.1 ⊓REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 5.11.2 REGULATORY FRAMEWORK 83 5.11.2.1 North America 84 5.11.2.1.1 US 84 5.11.2.2 Europe 84 5.11.2.3 Rest of the World 85 5.11.2.3.1 China 85 5.11.2.3.2 Brazil 85 5.11.2.3.3 Australia 85 5.12 PATENT ANALYSIS 86 5.12.1 ⊓URISDICTION AND TOP APPLICANT ANALYSIS 186 5.13 PRICING ANALYSIS 89 5.13.1∏AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021-2023[89 5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021-2023 91 5.14 KEY CONFERENCES & EVENTS, 2024-2026 92 5.15 ECOSYSTEM ANALYSIS 94 5.16 CASE STUDY ANALYSIS 95 5.17 REIMBURSEMENT ANALYSIS 97 5.18 UNMET NEEDS/END-USER EXPECTATIONS 97 5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 98 5.20 INVESTMENT & FUNDING SCENARIO 98 5.21 PIPELINE ANALYSIS 99 6 VETERINARY VACCINES MARKET, BY TYPE 101 6.1 INTRODUCTION 102 6.2 LIVESTOCK VACCINES 103 6.2.1 BOVINE VACCINES 105 6.2.1.1 Increasing demand for meat and milk to drive market 105 6.2.2 SMALL RUMINANT VACCINES 107 6.2.2.1 [Increased livestock population and favorable government initiatives to propel market growth [107 6.3 PORCINE VACCINES 109 6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH[109 6.4 POULTRY VACCINES 111 6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 111

6.5 COMPANION ANIMAL VACCINES 113 6.5.1 CANINE VACCINES 115 6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 115 6.5.2 FELINE VACCINES 117 6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 117 6.6 AQUACULTURE VACCINES 119 6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH 119 6.7 OTHER VETERINARY VACCINES 120 7 VETERINARY VACCINES MARKET, BY DISEASE 122 7.1 INTRODUCTION 123 7.2 LIVESTOCK DISEASES 123 7.2.1 BOVINE DISEASES 126 7.2.1.1 [Favorable government programs and increased awareness about animal health in emerging economies to aid market growth[]126 7.2.2 SMALL RUMINANT DISEASES 128 7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants 128 7.3 PORCINE DISEASES 130 7.3.1⊓INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF PIGS TO AID MARKET GROWTH 130 7.4 POULTRY DISEASES 132 7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR NEED FOR POULTRY VACCINES□132 7.5 COMPANION ANIMAL DISEASES 134 7.5.1 CANINE DISEASES 136 7.5.1.1 Rise in pet ownership in emerging economies to boost market growth 136 7.5.2 FELINE DISEASES 138 7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs 138 7.6 AQUACULTURE DISEASES 140 7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO SUPPORT MARKET GROWTH 140 7.7 OTHER VETERINARY DISEASES 142 8 VETERINARY VACCINES MARKET, BY TECHNOLOGY 144 8.1 INTRODUCTION 145 8.2 LIVE ATTENUATED VACCINES 145 8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH 145 8.3 INACTIVATED VACCINES 147 8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET 147 8.4 TOXOID VACCINES 149 8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 149 8.5 RECOMBINANT VACCINES 151 8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 151 8.6 OTHER VACCINE TECHNOLOGIES 153 9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 155

9.1 INTRODUCTION 156 9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 158 9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 158 9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 161 9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 161 9.4 ORAL ROUTE OF ADMINISTRATION 163 9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 163 9.5∏INTRANASAL/SPRAY ROUTE OF ADMINISTRATION∏165 9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 165 9.6⊓INTRAOCULAR ROUTE OF ADMINISTRATION⊓167 9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 167 9.7 OTHER ROUTES OF ADMINISTRATION 169 10 VETERINARY VACCINES MARKET, BY END USER 171 10.1 INTRODUCTION 172 10.2 VETERINARY HOSPITALS 172 10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET[]172 10.3 VETERINARY CLINICS 174 10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH 174 10.4 OTHER END USERS 176 11 VETERINARY VACCINES MARKET, BY REGION 177 11.1 INTRODUCTION 178 11.2 ASIA PACIFIC 182 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187 11.2.2 CHINA 189 11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 189 11.2.3 JAPAN 193 11.2.3.1 [High consumption of animal-derived products and increased pet health expenditure to propel market growth 193 11.2.4 INDIA 197 11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth 197 11.2.5 AUSTRALIA 202 11.2.5.1 Increase in per capita income and rise in meat consumption to aid market growth□202 11.2.6 SOUTH KOREA 206 11.2.6.1 [High demand for animal protein and favorable government subsidies for meat production to spur market growth 206 11.2.7 NEW ZEALAND 210 11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth 11.2.8 REST OF ASIA PACIFIC 214 11.3 NORTH AMERICA 218 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 223 11.3.2 US 224 11.3.2.1 US to dominate North American veterinary vaccines market during forecast period∏224 11.3.3 CANADA 228 11.3.3.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines[228

11.4[EUROPE[232 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 237 11.4.2 GERMANY 238 11.4.2.1 [Increased poultry consumption and high pet healthcare expenditure to drive market 238 11.4.3 UK 242 11.4.3.1 Rising adoption of pets to augment market growth 242 11.4.4 FRANCE 246 11.4.4.1 Rising companion animal and livestock population to boost market growth 246 11.4.5 || ITALY || 250 11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth 250 ? 11.4.6 SPAIN 254 11.4.6.1 [Increase in veterinary practices and willingness to spend on animal healthcare to drive market [254 11.4.7 NETHERLANDS 258 11.4.7.1 [High demand for meat and increased pressure on sustainable farming practices to fuel market growth]258 11.4.8 REST OF EUROPE 262 11.5 LATIN AMERICA 266 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 270 11.5.2 BRAZIL 271 11.5.2.1 Well-established livestock industry to promote market growth 271 11.5.3[MEXICO]275 11.5.3.1 Focus on pork and poultry meat production to fuel market growth 275 11.5.4 REST OF LATIN AMERICA 279 11.6 MIDDLE EAST & AFRICA 282 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 287 11.6.2 GCC COUNTRIES 288 11.6.2.1 Kingdom of Saudi Arabia 292 11.6.2.1.1 Pavorable government initiatives for better animal health infrastructure to propel market growth 292 11.6.2.2 UAE 296 11.6.2.2.1 Pavorable government initiatives to safeguard national livestock population and support sustainable agriculture 296 11.6.2.3 Rest of GCC countries 300 11.6.3 REST OF MIDDLE EAST & AFRICA 304 12 COMPETITIVE LANDSCAPE 308 12.1 INTRODUCTION 308 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 308 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 308 12.3 REVENUE ANALYSIS, 2019-2023 310 12.4 MARKET SHARE ANALYSIS, 2023 311 12.4.1 RANKING OF KEY MARKET PLAYERS, 2023 313 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 314 12.5.1[]STARS[]314 12.5.2 EMERGING LEADERS 314 12.5.3 PERVASIVE PLAYERS 314 12.5.4 PARTICIPANTS 314 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 316 12.5.5.1 Company footprint 316

12.5.5.2 Region footprint 317 12.5.5.3 Type footprint 318 ? 12.5.5.4 Disease footprint 319 12.5.5.5 Technology footprint 320 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 321 12.6.1 PROGRESSIVE COMPANIES 321 12.6.2 RESPONSIVE COMPANIES 321 12.6.3 DYNAMIC COMPANIES 321 12.6.4 STARTING BLOCKS 321 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 323 12.7 BRAND/PRODUCT COMPARISON 324 12.8 R&D EXPENDITURE OF KEY PLAYERS 325 12.9 COMPANY VALUATION & FINANCIAL METRICS 325 12.9.1 FINANCIAL METRICS 325 12.9.2 COMPANY VALUATION 326 12.10 COMPETITIVE SCENARIO 326 12.10.1 PRODUCT LAUNCHES & APPROVALS 326 12.10.2 DEALS 327 12.10.3 EXPANSIONS 328 12.10.4 OTHER DEVELOPMENTS 328 13 COMPANY PROFILES 329 13.1 KEY PLAYERS 329 13.1.1 MERCK & CO., INC. 329 13.1.1.1 Business overview 329 13.1.1.2 Products offered 330 13.1.1.3 Recent developments 333 13.1.1.3.1 Product launches & approvals 333 13.1.1.3.2 Deals 334 13.1.1.3.3 Expansions 334 13.1.1.3.4 Other developments 335 13.1.1.4 MnM view 335 13.1.1.4.1 Right to win 335 13.1.1.4.2 Strategic choices 335 13.1.1.4.3 Weaknesses & competitive threats 335 13.1.2 ZOETIS 336 13.1.2.1 Business overview 336 13.1.2.2 Products offered 337 13.1.2.3 Recent developments 339 13.1.2.3.1 Product launches 339 13.1.2.3.2 Deals 339 13.1.2.3.3 Expansions 339 13.1.2.3.4 Other developments 340 ? 13.1.2.4[]MnM view[]340 13.1.2.4.1 Right to win 340 13.1.2.4.2 Strategic choices 340

13.1.2.4.3 Weaknesses & competitive threats 340 13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 341 13.1.3.1 Business overview 341 13.1.3.2 Products offered 342 13.1.3.3 Recent developments 343 13.1.3.3.1 Product launches 343 13.1.3.3.2 Expansions 344 13.1.3.4 MnM view 344 13.1.3.4.1 Right to win 344 13.1.3.4.2 Strategic choices 344 13.1.3.4.3 Weaknesses & competitive threats 345 13.1.4 ELANCO 346 13.1.4.1 Business overview 346 13.1.4.2 Products offered 348 13.1.4.3 Recent developments 349 13.1.4.3.1 Deals 349 13.1.5 CEVA 350 13.1.5.1 Business overview 350 13.1.5.2 Products offered 350 13.1.5.3 Recent developments 352 13.1.5.3.1 Deals 352 13.1.5.3.2[Expansions]]353 13.1.6 VIRBAC 354 13.1.6.1 Business overview 354 13.1.6.2 Products offered 355 13.1.6.3 Recent developments 356 13.1.6.3.1 Product launches 356 13.1.6.3.2 Deals 357 13.1.6.3.3 Expansions 357 13.1.6.3.4 Other developments 358 13.1.7 PHIBRO ANIMAL HEALTH CORPORATION 359 13.1.7.1 Business overview 359 13.1.7.2 Products offered 360 13.1.8 HESTER BIOSCIENCES LIMITED 362 13.1.8.1 Business overview 362 13.1.8.2 Products offered 363 13.1.8.3 Recent developments 365 13.1.8.3.1 Deals 365 ? 13.1.9 NEOGEN CORPORATION 366 13.1.9.1 Business overview 366 13.1.9.2 Products offered 367 13.1.9.3 Recent developments 368 13.1.9.3.1 Deals 368 13.1.10 HIPRA 369 13.1.10.1 Business overview 369 13.1.10.2 Products offered 369

13.1.10.3 Recent developments 372 13.1.10.3.1 Product launches 372 13.1.11 BIOGENESIS BAGO 373 13.1.11.1 Business overview 373 13.1.11.2 Products offered 373 13.1.11.3 Recent developments 374 13.1.11.3.1 Expansions 374 13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 375 13.1.12.1 Business overview 375 13.1.12.2 Products offered 376 13.1.12.3 Recent developments 378 13.1.12.3.1 || Deals || 378 13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 7379 13.1.13.1 Business overview 379 13.1.13.2 Products offered 379 13.1.14 IINYU BIO-TECHNOLOGY CO., LTD. 381 13.1.14.1 Business overview 381 13.1.14.2 Products offered 382 13.1.14.3 Recent developments 384 13.1.14.3.1 Product approvals 384 13.1.15 VAXXINOVA INTERNATIONAL B.V. 385 13.1.15.1 Business overview 385 13.1.15.2 Products offered 386 13.1.15.3 Recent developments 387 13.1.15.3.1 Product approvals 387 13.1.15.3.2 Expansions 387 13.2 OTHER COMPANIES 388 13.2.1 ENDOVAC ANIMAL HEALTH 388 13.2.2 BRILLIANT BIO PHARMA 389 13.2.3 APTIMMUNE 390 13.2.4 INDIAN IMMUNOLOGICALS LTD. 391 13.2.5 TORIGEN PHARMACEUTICALS INC. 392 13.2.6 INTAS PHARMACEUTICALS LTD. 392 13.2.7 OUROFINO ANIMAL HEALTH 393 13.2.8 BIOVAC LTD. 394 13.2.9 LABORATOIRE LCV 395 13.2.10 KYORITSU SEIYAKU CORPORATION 396 14 APPENDIX 397 14.1 DISCUSSION GUIDE 397 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 403 14.3 CUSTOMIZATION OPTIONS 405 14.4 RELATED REPORTS 405 14.5 AUTHOR DETAILS 406



# Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Global Forecast to 2029

Market Report | 2025-01-22 | 407 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

### **ORDER FORM:**

| Select license | License                 |       | Price      |
|----------------|-------------------------|-------|------------|
|                | Single User             |       | \$4950.00  |
|                | Multi User              |       | \$6650.00  |
|                | Corporate License       |       | \$8150.00  |
|                | Enterprise Site License |       | \$10000.00 |
|                |                         | VAT   |            |
|                |                         | Total |            |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| Email*        | Phone*                |         |
|---------------|-----------------------|---------|
| First Name*   | Last Name*            |         |
| Job title*    |                       |         |
| Company Name* | EU Vat / Tax ID / NIF | number* |
| Address*      | City*                 |         |

| Zip  | Code* |
|------|-------|
| - 10 | Couc  |

Country\*

Date

Signature

2025-05-19